Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40
mg per day of istradefylline (KW6002) in patients with Restless Legs Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.